NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»05/02/2010 [Industry news]
Huifeng Bio-Pharma anticipates 30% revenue growth for 2009

Huifeng Bio- Pharmaceutical Technology, a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, announced preliminary 2009 results and provided guidance for 2010.

 
Huifeng Bio- Pharmaceutical Technology, a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, announced preliminary 2009 results and provided guidance for 2010. Huifeng Bio-Pharmaceutical Technology anticipates revenues between $13 million to $14 million for the full year ended December 31, 2009. This represents a year-over-year revenue growth of 27% to 35%. Preliminary 2009 net income is anticipated to be between $2.8 million to $3.0 million for the year, representing 80% to 93% year-over-year growth. \"The increase was attributed to the increase in the company\'s sales of pharmaceutical raw-material and Plant Extractive, and other products, including Rutin, Quercetin, injectable Troxerutin and Diosmin,\" said Jing\'An Wang, CEO, Huifeng Bio- Pharmaceutical Technology. \"The increase in revenue reflected both a gain in new customers, as well as an increase in the number of orders from our existing customers.\" The company noted that the management is providing revenue guidance of $20 million to $25 million and net income guidance between $4.5 million to $5.0 million for 2010. Growth is expected to be driven by increasing sales of current products. Because of the EU COS for Diosmin, the company has a high level diosmin quality. Certain European customers will be interested in Huifeng\'s diosmin and will increase their purchasing quantity from the company. The company will begin to perform the contract with Safic-Alan for diosmin. Another driver is production line expansion and acquisition which will increase the production quantity of diosmin. This will meet the big quantity requirement of new orders.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.